title: Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.
abstract: BACKGROUND
  The ACVBP regimen is an efficient induction regimen for poor-risk patients with diffuse large B-cell lymphoma (DLBCL) before consolidative autologous stem cell transplantation. Adjunction of the monoclonal anti-CD20 antibody rituximab (R-ACVBP) was recently found to be superior to ACVBP alone. This study assessed the impact of rituximab on stem cell mobilization in two similar consecutive groups of patients treated with ACVBP in two prospective, controlled trials.
  
  
  METHODS
  The first trial (LNH-98B-3) involved 137 patients treated with ACVBP alone. In the second trial (LNH-03-3B), 91 patients received an R-ACVBP regimen. Stem cell mobilization was performed after a course of (R)-ACVBP.
  
  
  RESULTS
  The median peak numbers of blood CD34+ cell counts recorded before the first apheresis procedure in the ACVBP and R-ACVBP groups were 69×10(6) and 63×10(6) /L, respectively (p=0.55). The median numbers of CD34+ cells collected were 7.1×10(6) and 6.0×10(6) CD34+ cells/kg for the ACVBP and R-ACVBP groups, respectively (p=0.13). The median number of apheresis procedures required for gathering the minimum amount of CD34+ cells (2×10(6) /kg) was the same in the two groups.
  
  
  CONCLUSIONS
  When compared with ACVBP alone, adjunction of rituximab does not impair stem cell mobilization.
authors.affiliation: Département de Biothérapie, Hôpital Necker, AP-HP, Paris, France. francois.lefrere@nck.aphp.fr
authors.forename: François
authors.initials: F
authors.lastname: Lefrère
authors.forename: Dominique
authors.initials: D
authors.lastname: Bastit-Barrau
authors.forename: Olivier
authors.initials: O
authors.lastname: Hequet
authors.forename: Philippe
authors.initials: P
authors.lastname: Bourin
authors.forename: Suzanne
authors.initials: S
authors.lastname: Mathieu-Nafissi
authors.forename: Alain
authors.initials: A
authors.lastname: Bohbot
authors.forename: Hervé
authors.initials: H
authors.lastname: Tilly
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
authors.forename: Christophe
authors.initials: C
authors.lastname: Fermé
authors.forename: Valérie
authors.initials: V
authors.lastname: Lapierre
authors.forename: Luc
authors.initials: L
authors.lastname: Fornecker
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Micléa
authors.forename: Loic
authors.initials: L
authors.lastname: Isebaert
authors.forename: Serge
authors.initials: S
authors.lastname: Bologna
authors.forename: Olivier
authors.initials: O
authors.lastname: Fitoussi
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
mesh_terms: D000293:Adolescent; D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018952:Antigens, CD34 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014751:Vindesine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018952:Antigens, CD34; D001761:Bleomycin; D000069283:Rituximab; D004317:Doxorubicin; D003520:Cyclophosphamide; D014751:Vindesine; D011241:Prednisone